Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Obama Announces Agreement with Drug Companies

By Pharmaceutical Processing | June 22, 2009

JENNIFER LOVEN AP White House Correspondent WASHINGTON (AP) — President Barack Obama on Monday welcomed the pharmaceutical industry’s agreement to help close a gap in Medicare’s drug coverage, calling the pact a step forward in the push for overhaul of the nation’s health care system. Obama said that drug companies have pledged to spend $80 billion over the next decade to help reduce the cost of drugs for seniors and pay for a portion of Obama’s health care legislation. The agreement with the pharmaceutical industry would help close a gap in prescription drug coverage under Medicare. “This is a significant breakthrough on the road to health care reform, one that will make a difference in the lives of many older Americans,” Obama said in the White House’s Diplomatic Room. He was joined by Sen. Max Baucus, D-Mont., the chairman of the Senate Finance Committee who struck the deal with the White House; Sen. Chris Dodd, D-Conn., and Barry Rand, head of the senior citizens’ advocacy group AARP. Notably absent was a representative from the pharmaceutical association. “It was always designed to be an AARP event,” said Ken Johnson, spokesman for the association. “We don’t think we should have been invited to it.” Johnson said Billy Tauzin, the group’s president and a former Republican congressman from Louisiana, will attend a town hall meeting on health care that Obama is staging at the White House on Wednesday. Johnson said there are other parts to the agreement that have still not been completed, but he declined to provide details. “There are a lot of discussions going on right now, there are a lot of moving pieces, there are a lot of elements to it that have not been finalized,” Johnson said. The president used the opportunity to make his sternest call yet for action, saying the drug agreement is one piece of “health care reform I expect Congress to enact this year.” Obama said the move on Medicare will help correct an anomaly in the program that provides a prescription drug benefit through the government health care program for the elderly and disabled. Under the deal, drug companies will pay part of the cost of brand name drugs for lower and middle-income older people in the so-called “doughnut hole.” That term refers to a feature of the current drug program that requires beneficiaries to pay the entire cost of prescriptions after initial coverage is exhausted but before catastrophic coverage begins. Obama said some Medicare beneficiaries will find at least a 50 percent discount on prescription drugs. Obama says drug companies stand to benefit when more Americans can afford prescription drugs. The drug companies’ investment would reduce the cost of drugs for seniors and pay for a portion of Obama’s proposed revamping of health care. “This is an early win for reform,” Rand said. Under the agreement, part of the $80 billion would be used to halve the cost of brand name drugs for Medicare recipients when they are in a coverage gap of the program. AARP, which represents 40 million older Americans, has long lobbied to eliminate that coverage gap completely. The deal would affect about 26 million low- and middle-income recipients of the program’s enrollees, AARP said. It would apply to brand name and biologic drugs, but not generics, the group said, and likely take effect in July 2010, assuming drug overhaul legislation becomes law. Under Medicare’s Part D prescription drug program, recipients pay about 25 percent of the cost of their drugs until they and the government have paid $2,700. At that point, beneficiaries must cover the full cost of drugs until they have spent $4,350 from their own pockets. When they reach that amount, Medicare’s catastrophic drug benefit takes effect, and recipients only pay 5 percent of their drugs’ costs until the end of the year.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE